Last reviewed · How we verify
nausea — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Dimenhydrinate | DIMENHYDRINATE | Alra | dimenhydrinate | Histamine H1 receptor | 1972-01-01 | |
| Ethylthioperazine | THIETHYLPERAZINE | Novartis | thiethylperazine | Alpha-1A adrenergic receptor | 1961-01-01 | |
| Pollutox | OZONE | Deseret Biologicals, Inc. | Radiographic Contrast Agent [EPC] | |||
| Aspartame/MSG Detox | MALTODEXTRIN | Deseret Biologicals, Inc. | Standardized Chemical Allergen [EPC] |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in nausea
- Deseret Biologicals, Inc. · 2 drugs in nausea
- Alra · 1 drug in nausea
- Novartis · 1 drug in nausea
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in nausea:
Cite this brief
Drug Landscape (2026). nausea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nausea. Accessed 2026-06-10.
Related
- nausea full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing